Ipsen: Société Générale upgrades to buy.
(CercleFinance.com) - Société Générale (SG) has upgraded its hold rating on the share of the French pharmaceutical group Ipsen this morning to buy.
"Even more growth to come," says its research report, which has also raised its 12-month target price from 111 euros to 126 euros.
"We are again upgrading our Ipsen outlook on the excellent data (and solid presentation) given for Cabo at ESMO." (European company for medical oncology), SG explains.
Last May, Ipsen raised its target for revenues by 2020 to over 2.5 billion euros, "driven by Specialty care sales growth of at least 14% pa, and a core operating margin above 30% even if Somatuline is genericized."
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"Even more growth to come," says its research report, which has also raised its 12-month target price from 111 euros to 126 euros.
"We are again upgrading our Ipsen outlook on the excellent data (and solid presentation) given for Cabo at ESMO." (European company for medical oncology), SG explains.
Last May, Ipsen raised its target for revenues by 2020 to over 2.5 billion euros, "driven by Specialty care sales growth of at least 14% pa, and a core operating margin above 30% even if Somatuline is genericized."
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.